可以直接在线观看av的网站,巨大胸大乳美女在办公室高潮,久久亚洲sm情趣捆绑调教

當(dāng)前只顯示滿足指定條件的回帖，點(diǎn)擊這里查看本話題的所有回帖

常八九無二三

新蟲 (初入文壇)

應(yīng)助: 0 (幼兒園)
金幣: 226.9
帖子: 27
在線: 3.2小時(shí)
蟲號(hào): 6467006

已領(lǐng)完

投稿第一篇SCI，7月份收到編輯部回信，請(qǐng)問修回后中的機(jī)會(huì)大不大啊: 領(lǐng)取紅包 (小木蟲手機(jī)app專屬紅包)

掃一掃，下載小木蟲客戶端

意見如下

Reviewers' comments:
------------------------------------------------------
Reviewer E:

The manuscript by Wu et al. reviews the role of Gli-associated oncogenes, in
particular Gli-1, in cancer development, and as a potential target for
cancer therapy.  Gli-1 is an important oncogene and is found to be
overexpressed in a variety of cancers. The manuscript provides a good
overview of the current state of knowledge of the role of Gli-1 in mediating
signalling through the Hedgehog pathway, and how alterations in Gli-1 may
contribute to cancer development.  The manuscript also focuses on the
potential of inhibitors of Gli-1 and other components of the Hedgehog
pathway to be used in cancer therapy.  An extensive reference list is
provided, covering relevant articles in the field.

However, there are two major issues with the current manuscript which must
be corrected before it could be published.

1. The grammar requires extensive correction, as the errors detract
significantly from the meaning of the key points, and would make it
difficult for readers to fully understand the points being made in the
review.

2. In particular in the discussion of inhibitors of Gli-1 and other
components of the Hedgehog pathway, a clear distinction must be made between
effects demonstrated in cell culture, models, in xenograft experiments in
animal models, and effects in clinical trials.  This distinction is not
clear in the present manuscript, and this will lead to confusion on the part
of readers as to the current state of development of Gli-1 inhibitors for
cancer treatment. For example, resveratrol is described as a medicine
(Section 1.3), but this may be an overstatement. A more critical analysis
of the data with regard to potential Gli inhibitors is required in order for
the review to be of maximum benefit to cancer researchers.

Reviewer L:

The work titled “Glioma-associated oncogene especially Gli-1 function in
the carcinogenesis and cancer targeted therapy” is based on an interesting
area. The work can be considered for publication; however, it needs some
serious revisions before its acceptance. The manuscript must be revised as
per following comments-
1. The title looks difficult to understand, it may be revised something like
Role of glioma-associated Gli-1 oncogene in the carcinogenesis and cancer
targeted therapy.
2. Information provided in the manuscript is not adequate as I can see few
important researches like “Scientific Reports 6, Article number: 22184
(2016)”, BMC Cancer. 2009;9:298, etc. are not included.
3. Language editing is also required as few phrases are written
grammatically wrong for example, “in abstract section - Glioma-associated
oncogene (Gli) belongs…”; “in introduction - therapeutic target for
cancers…; resveratrol and cyclopamine”; “GLI-1 CLOSLY RELATED”;
“Moreover,…”; “exerts anticancer effects through”; “ITRA, an
inhibitor of Smo”, etc.
4. Delete phrase “In our review, we summarized the Gli function in the
carcinogenesis and cancer targeted therapy” from introduction section as
it is also written in the abstract.

------------------------------------------------------
Editorial comments:

This MS covers a good topic. However, there are major concerns over the
presentation and the language quality. The following should be carefully
addressed by the authors:

1. The rationale and the significance should be clearly stated in the
introduction section.
2. The abstract should be expanded to cover the major findings in the field.
3. The references should be updated.
4. A professional editing for language and style is needed. A certificate
for such an editing should be provided when resubmitting this MS.
5. The CCDT format should be followed.

-----------------------------------------------------

發(fā)自小木蟲Android客戶端

[ Last edited by 常八九無二三 on 2017-8-27 at 14:56 ]

回復(fù)此樓

» 猜你喜歡

【求調(diào)劑】新能源材料本科，一志愿211，初試321 已經(jīng)有3人回復(fù)
材料考研調(diào)劑已經(jīng)有3人回復(fù)
材料調(diào)劑已經(jīng)有12人回復(fù)
英一數(shù)一408，總分284，二戰(zhàn)真誠求調(diào)劑已經(jīng)有14人回復(fù)
085410 一志愿211 22408分?jǐn)?shù)359求調(diào)劑已經(jīng)有4人回復(fù)
271求調(diào)劑已經(jīng)有19人回復(fù)
385分生物學(xué)（071000）求調(diào)劑已經(jīng)有3人回復(fù)
一志愿安徽大學(xué)計(jì)算機(jī)科學(xué)與技術(shù)學(xué)碩，331分求調(diào)劑已經(jīng)有3人回復(fù)
318求調(diào)劑，計(jì)算材料方向已經(jīng)有8人回復(fù)
291求調(diào)劑已經(jīng)有25人回復(fù)

» 搶金幣啦！回帖就可以得到:

查看全部散金貼

1樓 2017-08-27 14:40:21

已閱回復(fù)此樓關(guān)注TA 給TA發(fā)消息送TA紅花 TA的回帖

蝦米愛蟲蟲

新蟲 (小有名氣)

應(yīng)助: 0 (幼兒園)
金幣: 86.1
帖子: 144
在線: 6.3小時(shí)
蟲號(hào): 5467352

★
liouzhan654: 金幣+1, 感謝交流 2017-08-27 15:07:57

讓修改機(jī)會(huì)就大

發(fā)自小木蟲IOS客戶端

回復(fù)此樓

9樓2017-08-27 14:52:12

已閱回復(fù)此樓關(guān)注TA 給TA發(fā)消息送TA紅花 TA的回帖

查看全部 16 個(gè)回答

瑟可米瑟

新蟲 (正式寫手)

應(yīng)助: 3 (幼兒園)
金幣: 3805.5
帖子: 345
在線: 64.8小時(shí)
蟲號(hào): 3507329

挺大啊

發(fā)自小木蟲Android客戶端

回復(fù)此樓

10樓2017-08-27 14:56:17

已閱回復(fù)此樓關(guān)注TA 給TA發(fā)消息送TA紅花 TA的回帖

小川哲夢(mèng)

鐵桿木蟲 (著名寫手)

應(yīng)助: 90 (初中生)
金幣: 7355.1
帖子: 2385
在線: 255.7小時(shí)
蟲號(hào): 2183096

★
小木蟲: 金幣+0.5, 給個(gè)紅包，謝謝回帖

好好修改，機(jī)會(huì)還是蠻大的，最怕就是連修改的機(jī)會(huì)都沒有。

發(fā)自小木蟲IOS客戶端

贊一下(1人)

回復(fù)此樓

11樓2017-08-27 21:38:30

已閱回復(fù)此樓關(guān)注TA 給TA發(fā)消息送TA紅花 TA的回帖

caolinzk789

禁蟲 (正式寫手)

★
小木蟲: 金幣+0.5, 給個(gè)紅包，謝謝回帖

本帖內(nèi)容被屏蔽

14樓2017-09-02 01:43:47

已閱回復(fù)此樓關(guān)注TA 給TA發(fā)消息送TA紅花 TA的回帖

簡(jiǎn)單回復(fù)

zzjj_2073樓

2017-08-27 14:40 回復(fù)

常八九無二三(金幣+1): 謝謝參與

已獲得1個(gè)金幣發(fā)自小木蟲IOS客戶端

逝水無痕199012樓

2017-08-27 23:12 回復(fù)

祝福發(fā)自小木蟲IOS客戶端

橘色翡冷翠2樓

2017-08-27 14:40 回復(fù)

常八九無二三(金幣+2): 謝謝參與

已獲得2個(gè)金幣發(fā)自小木蟲Android客戶端

54061623613樓

2017-08-28 06:17 回復(fù)

祝福發(fā)自小木蟲IOS客戶端

FQ11118樓

2017-08-27 14:40 回復(fù)

常八九無二三(金幣+2): 謝謝參與

已獲得2個(gè)金幣發(fā)自小木蟲Android客戶端

oil-shale4樓

2017-08-27 14:40 回復(fù)

常八九無二三(金幣+1): 謝謝參與

已獲得1個(gè)金幣發(fā)自小木蟲Android客戶端

常清泉6樓

2017-08-27 14:40 回復(fù)

常八九無二三(金幣+1): 謝謝參與

已獲得1個(gè)金幣發(fā)自小木蟲Android客戶端

hlj格�；�7樓

2017-08-27 14:40 回復(fù)

常八九無二三(金幣+1): 謝謝參與

已獲得1個(gè)金幣發(fā)自小木蟲Android客戶端

150294815325樓

2017-08-27 14:40 回復(fù)

常八九無二三(金幣+2): 謝謝參與

已獲得2個(gè)金幣發(fā)自小木蟲Android客戶端

最具人氣熱帖推薦 [查看全部]	作者	回/看	最后發(fā)表

[考研] 318求調(diào)劑，計(jì)算材料方向 +7	吸喵有害笙命 2026-04-01	8/400	2026-04-01 23:54 by 義文wang
[考研] 085602化學(xué)工程268分蹲調(diào)劑 +8	月照花林。 2026-04-01	8/400	2026-04-01 22:08 by 無際的草原
[考研] 286求調(diào)劑 +16	PolarBear11 2026-03-26	16/800	2026-04-01 21:31 by 七度不信任
[考研] 349求調(diào)劑 +6	吃的不少 2026-04-01	6/300	2026-04-01 17:55 by JYD2011
[考研] 英一數(shù)二生物信息學(xué)287分，本科生物科學(xué)，求調(diào)劑 +3	碧水xyz 2026-03-29	4/200	2026-04-01 15:35 by plum
[考研] 一志愿中國科學(xué)院大學(xué)265求調(diào)劑 +8	恬淡ye 2026-03-31	9/450	2026-04-01 14:34 by 逆水乘風(fēng)
[考研] 一志愿南昌大學(xué)324求調(diào)劑 +7	hanamiko 2026-03-30	7/350	2026-04-01 13:22 by JourneyLucky
[碩博家園] 博一被送出聯(lián)培感覺不適應(yīng)怎么辦 +3	全村的狗 2026-03-31	3/150	2026-04-01 10:44 by 328838485
[考研] 0856材料化工調(diào)劑總分330 +18	zhubinhao 2026-03-27	18/900	2026-04-01 09:37 by oooqiao
[考研] 考研材料工程351分調(diào)劑 +5	整個(gè)好的 2026-03-31	5/250	2026-04-01 09:36 by topgun2009
[考研] 0856材料與化工調(diào)劑，339 +10	10213207 2026-03-31	10/500	2026-04-01 08:28 by Linda Hu
[考博] 26申博 +4	加油沖�。� 2026-03-26	4/200	2026-03-31 22:42 by greychen00
[考研] 一志愿南昌大學(xué)324求調(diào)劑 +6	hanamiko 2026-03-29	6/300	2026-03-31 16:35 by hypershenger
[考研] 353求調(diào)劑 +3	江上楓_26 2026-03-28	3/150	2026-03-31 15:53 by jp9609
[考研] 08工科求調(diào)劑286 +5	tgs_001 2026-03-28	5/250	2026-03-31 08:18 by 一只好果子?
[考研] 福建理工大學(xué)材料學(xué)院先進(jìn)合金團(tuán)隊(duì)招收考研調(diào)劑學(xué)生 +3	大華金商都 2026-03-30	4/200	2026-03-31 01:04 by 方英俊602
[考研] 322求調(diào)劑 +10	宋明欣 2026-03-27	10/500	2026-03-30 18:47 by 544594351
[考研] 一志愿廈門大學(xué)材料工程專碩354找調(diào)劑�。�！ +5	貝唄鋇鋇 2026-03-30	5/250	2026-03-30 18:16 by 無際的草原
[考研] 332求92調(diào)劑 +8	蕉蕉123 2026-03-28	8/400	2026-03-29 10:46 by 周梓丹
[考研] 085602化學(xué)工程求調(diào)劑。 +4	平樂樂樂 2026-03-26	4/200	2026-03-26 17:57 by fmesaito